ENDPOINTS

Lilly pays $10M upfront for Organovo’s FXR agonist program

Eli Lilly is buying Organovo’s farnesoid X receptor (FXR) agonist program, which includes a drug in Phase 2 development for ulcerative colitis and metabolic dysfunction-associated steatohepatitis (MASH), the biotech said Tuesday ...

Feb 25, 2025 - 16:49
 0
Lilly pays $10M upfront for Organovo’s FXR agonist program
Eli Lilly is buying Organovo’s farnesoid X receptor (FXR) agonist program, which includes a drug in Phase 2 development for ulcerative colitis and metabolic dysfunction-associated steatohepatitis (MASH), the biotech said Tuesday ...
Read More

Tags:

Previous Article

Why Widening Highways Doesn’t Fix Traffic—But Congestion Pricing Can

Next Article

Indian drugmakers join forces to boost national biomanufacturing sector  

Related Posts

#ASCOGU: Corbus shares dip on mixed Phase 1 solid tumor data for Nectin-4 ADC

#ASCOGU: Corbus shares dip on mixed Phase 1 solid tumor...

Feb 14, 2025  0

Some FDA medical device staff reinstated just days after firings

Some FDA medical device staff reinstated just days afte...

Feb 24, 2025  0

Belgian regulator recommends blocking Indian drugmaker's API production

Belgian regulator recommends blocking Indian drugmaker'...

Feb 9, 2025  0